Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection

Next Previous
Trial Profile

A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenacapavir (Primary) ; Lenacapavir (Primary) ; Teropavimab (Primary) ; Zinlirvimab (Primary) ; Abacavir/dolutegravir/lamivudine; Bictegravir/emtricitabine/tenofovir alafenamide; Cobicistat/darunavir/emtricitabine/tenofovir alafenamide; Emtricitabine/rilpivirine/tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences

Most Recent Events

  • 15 Oct 2025 According to a Gilead Sciences media release, data from this trial will be presented at the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18.
  • 12 Mar 2025 According to a Gilead Sciences media release, the company presented data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
  • 12 Mar 2025 Results presented in the Gilead Sciences Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top